mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Moderna and Merck announced that their mRNA cancer vaccine met its primary endpoint in a Phase 3 melanoma trial. The companies stated the vaccine reduced the risk of recurrence or death in melanoma patients when combined with Merck's Keytruda immunotherapy. The trial enrolled patients with resected melanoma, according to the companies' announcement.

Next story